Zuellig Pharma, the region's leading healthcare services provider, has today announced it has invested in Health Benefit Consultants Company (HBC) through its Malaysian subsidiary – MiCare Sdn Bhd.
HBC is a leading third party administrator in Thailand providing medical claims administration and related consulting and advisory services to corporates and insurance companies. It was established in 1993 and serves the needs of 17 Thai and three foreign companies.
Zuellig Pharma Vice President Integrated Solutions Moses Hee said this partnership will focus on growing HBC in Thailand and expanding the services and health benefits it offers to Thai people.
"We want to work closely with HBC to grow its existing business and help it better serve the needs of local Thai people, companies and insurers. The business is currently responsible for managing the health insurance of 2.5 million Thai people and we believe that there is a lot of potential for growth."
HBC Managing Director Permsak Natenuj said the partnership will allow HBC to leverage Zuellig Pharma's regional networks and MiCare's technology and expertise.
"Zuellig Pharma's strong regional networks and focus on developing innovative new solutions will help us to expand HBC's business and the services that we offer. This partnership will enable the development of technology and solutions that will deliver greater health benefits to the Thai people that we support."
Zuellig Pharma's subsidiary, MiCare, is the leading partner for Payors in Malaysia, offering health and wellness as well as third party administration services to corporates and insurance companies. Zuellig Pharma will leverage MiCare's technology and expertise to bring new services to Thailand, in partnership with HBC.
"MiCare offers corporates and insurance companies a range of services to improve the health of the people that they insure. This is not only good for the individual, it helps to reduce corporate healthcare and insurance costs," said Mr Hee.
The solutions being piloted in Malaysia include mobile applications and health and wellness programmes.
"These programmes are delivering strong results. A recent pilot that we ran with a local Malaysian corporate reduced the number of preventable new cases of chronic disease among its employees by 20% and improved the health of more than 45% of the people that took part.
"This resulted in a 14% reduction in the company's absentee rate and a 15% reduction in its employee medical expenses. We look forward to introducing similar programmes to the Thai market through our partnership with HBC," said Mr Hee.
HBC is a leading third party administrator in Thailand providing medical claims administration and related consulting and advisory services to corporates and insurance companies. It was established in 1993 and serves the needs of 17 Thai and three foreign companies.
Zuellig Pharma Vice President Integrated Solutions Moses Hee said this partnership will focus on growing HBC in Thailand and expanding the services and health benefits it offers to Thai people.
"We want to work closely with HBC to grow its existing business and help it better serve the needs of local Thai people, companies and insurers. The business is currently responsible for managing the health insurance of 2.5 million Thai people and we believe that there is a lot of potential for growth."
HBC Managing Director Permsak Natenuj said the partnership will allow HBC to leverage Zuellig Pharma's regional networks and MiCare's technology and expertise.
"Zuellig Pharma's strong regional networks and focus on developing innovative new solutions will help us to expand HBC's business and the services that we offer. This partnership will enable the development of technology and solutions that will deliver greater health benefits to the Thai people that we support."
Zuellig Pharma's subsidiary, MiCare, is the leading partner for Payors in Malaysia, offering health and wellness as well as third party administration services to corporates and insurance companies. Zuellig Pharma will leverage MiCare's technology and expertise to bring new services to Thailand, in partnership with HBC.
"MiCare offers corporates and insurance companies a range of services to improve the health of the people that they insure. This is not only good for the individual, it helps to reduce corporate healthcare and insurance costs," said Mr Hee.
The solutions being piloted in Malaysia include mobile applications and health and wellness programmes.
"These programmes are delivering strong results. A recent pilot that we ran with a local Malaysian corporate reduced the number of preventable new cases of chronic disease among its employees by 20% and improved the health of more than 45% of the people that took part.
"This resulted in a 14% reduction in the company's absentee rate and a 15% reduction in its employee medical expenses. We look forward to introducing similar programmes to the Thai market through our partnership with HBC," said Mr Hee.
Zuellig Pharma Launches "Obesity is a Disease" Seminar as Part of "Reduce Size, Reduce Disease" Campaign
ซิลลิค ฟาร์มา ขับเคลื่อนการดูแลโรคอ้วนอย่างปลอดภัยและยั่งยืน จัดเสวนาชูประเด็น "อ้วนคือโรค" พร้อมเดินหน้าต่อโครงการ 'ลดไซซ์ ลดโรค'
Zuellig Pharma launches "Obesity is a Disease" seminar as part of "Reduce Size, Reduce Disease" Campaign
Thammasat Hospital partners with Zuellig Pharma to fight obesity through the "Reduce Size, Reduce Disease" campaign
โรงพยาบาลธรรมศาสตร์ฯ ผนึกกำลัง ซิลลิค ฟาร์มา เปิดตัวแคมเปญ "ลดไซซ์ ลดโรค" ยกระดับการดูแลผู้ป่วยโรคอ้วนในไทย
Zuellig Pharma Launches "Reduce Size, Reduce Disease" Campaign in Thailand This campaign aims to raise awareness of obesity as a disease and promote healthier lifestyles nationwide
ซิลลิค ฟาร์มา เปิดตัวโครงการ "ลดไซซ์ ลดโรค" ในไทย มุ่งสร้างความเข้าใจเรื่องโรคอ้วนในฐานะปัญหาสุขภาพ พร้อมทั้งส่งเสริมวิถีชีวิตที่เอื้อต่อสุขภาพที่ดีขึ้นทั่วประเทศ
ซิลลิค ฟาร์มา เปิดตัวนวัตกรรมยาใหม่สำหรับรักษาโรคอ้วนและโรคเบาหวานในประเทศไทย มอนจาโร (เทอเซพาไทด์) จะมาถึงไทยในปลายเดือนพฤษภาคม 2568
Zuellig Pharma Launches Lilly's Innovative Obesity and Diabetes Medicine in Thailand Mounjaro(R) (tirzepatide) will be available in the market from the end of May 2025